字體大小: 字級放大   字級縮小   預設字形  

詳目顯示

以作者查詢圖書館館藏以作者&題名查詢臺灣博碩士以作者查詢全國書目
研究生中文姓名:何欣容
研究生英文姓名:Ho, Sing-Zong
中文論文名稱:豆科植物粗萃物及化合物對乳癌的藥理作用與機制
英文論文名稱:Pharmacological and mechanistic studies of Leguminosae plant extracts and compounds for breast cancer
指導教授姓名:楊文欽
口試委員中文姓名:助理教授︰廖柏凱
教授︰葉添順
教授︰楊文欽
學位類別:碩士
校院名稱:國立臺灣海洋大學
系所名稱:水產養殖學系
學號:10633027
請選擇論文為:學術型
畢業年度:108
畢業學年度:107
學期:
語文別:中文
論文頁數:35
中文關鍵詞:乳癌豆科植物抗細胞增生誘導細胞凋亡檢查點機酶MCF-7乳癌模式鼠免疫組織染色
英文關鍵字:Breast cancerLeguminosae familyanti-proliferationapoptosischeckpoint kinasesMCF-7 tumor-bearing miceimmunohistochemistry
相關次數:
  • 推薦推薦:0
  • 點閱點閱:19
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:13
  • 收藏收藏:0
致謝
摘要
Abstract
目錄
圖目錄
第一章、前言
第一節、乳癌及其治療限制
第二節、細胞週期與癌症進程
第三節、中草藥及癌症
第四節、豆科植物
第五節、實驗目標
第二章、材料及方法
第一節、細胞實驗部分
第二節、動物實驗部分
第三節、統計分析
第三章、結果
第一節、乳癌冷光模式鼠的建立
第二節、給予粗萃物治療能抑制MCF-7乳癌荷瘤小鼠的腫瘤成長
第三節、粗萃物能延長MCF-7乳癌荷瘤小鼠的存活率與壽命
第四節、粗萃物藉由抑制MCF-7細胞增生、促進細胞凋亡抑制腫瘤
第五節、化合物的複合治療能抑制MCF-7荷瘤小鼠之腫瘤生長,並延長存活
第六節、Cpd4及Cpd7利用不同機制影響檢查點激酶 (CHK),抑制MCF-7細胞增生並促進凋亡
第四章、實驗討論
第一節、冷光乳癌模式鼠的建立
第二節、 PC的粗萃物與化合物可透過影響細胞週期抑制乳癌細胞的增生
第三節、粗萃物與化合物有良好的抑制活體腫瘤生長效果,並能延長小鼠存活
第四節、總結
第五章、實驗圖表
第六章、參考文獻
1. Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA Cancer J Clin, 2013. 63(1): p. 11-30.
2. Westphal, T., et al., Cure in metastatic breast cancer. Memo, 2018. 11(3): p. 172-179.
3. Qi, F., et al., Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends, 2010. 4(6): p. 297-307.
4. Safarzadeh, E., S. Sandoghchian Shotorbani, and B. Baradaran, Herbal medicine as inducers of apoptosis in cancer treatment. Advanced pharmaceutical bulletin, 2014. 4(Suppl 1): p. 421-427.
5. Pereira, D.M., et al., Plant secondary metabolites in cancer chemotherapy: where are we? Curr Pharm Biotechnol, 2012. 13(5): p. 632-50.
6. Makki, J., Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol, 2015. 8: p. 23-31.
7. Ralhan, R., et al., Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett, 2007. 248(1): p. 1-17.
8. Ouyang, L., et al., Plant natural products: from traditional compounds to new emerging drugs in cancer therapy. Cell Prolif, 2014. 47(6): p. 506-15.
9. Yaswen, P., et al., Therapeutic targeting of replicative immortality. Semin Cancer Biol, 2015. 35: p. 104-128.
10. Tourrière, H. and P. Pasero, Maintenance of fork integrity at damaged DNA and natural pause sites. DNA Repair, 2007. 6(7): p. 900-913.
11. Aguilera, A. and B. Gómez-González, Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet., 2008. 9: p. 204.
12. Yao, Y. and W. Dai, Genomic Instability and Cancer. J carcinog mutagen, 2014. 5: p. 1000165.
13. Hanahan, D. and Robert A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell, 2011. 144(5): p. 646-674.
14. Halazonetis, T.D., V.G. Gorgoulis, and J. Bartek, An Oncogene-Induced DNA Damage Model for Cancer Development. Science, 2008. 319(5868): p. 1352-1355.
15. Yang, Y., et al., Genomic Instability in Precancerous Lesions before Inactivation of Tumor Suppressors p53 and APC in Patients. Cell Cycle, 2006. 5(13): p. 1443-1447.
16. Gaillard, H., T. García-Muse, and A. Aguilera, Replication stress and cancer. Nature Reviews Cancer, 2015. 15: p. 276.
17. Kaye, S.B., New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer, 1998. 78: p. 1-7.
18. Al-Kaabi, M.M., et al., Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. Br J Cancer, 2015. 112(5): p. 901-911.
19. Apostolou, P. and I. Papasotiriou, Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer (Dove Med Press), 2017. 9: p. 331-335.
20. Bartek, J. and J. Lukas, Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 2003. 3(5): p. 421-429.
21. Smith, J., et al., Chapter 3 - The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer, in Advances in Cancer Research, Adv Cancer Res, 2010. 108: p. 73-112.
22. Ezoe, S., Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health, 2012. 9(7): p. 2444-2453.
23. Mosihuzzaman, M., Herbal medicine in healthcare--an overview. Nat Prod Commun, 2012. 7(6): p. 807-12.
24. Newman, D.J. and G.M. Cragg, Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod, 2016. 79(3): p. 629-661.
25. Li-Weber, M., Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett, 2013. 332(2): p. 304-12.
26. Meeran, S.M., S. Katiyar, and S.K. Katiyar, Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol, 2008. 229(1): p. 33-43.
27. Wang, L., L. Lin, and B. Ye, Electrochemical studies of the interaction of the anticancer herbal drug emodin with DNA. J Pharm Biomed Anal, 2006. 42(5): p. 625-629.
28. Rakotoarivelo, N.H., et al., Medicinal plants used to treat the most frequent diseases encountered in Ambalabe rural community, Eastern Madagascar. J Ethnobiol Ethnomed, 2015. 11: p. 68-68.
29. Rayanil, K.-o., P. Bunchornmaspan, and P. Tuntiwachwuttikul, A new phenolic compound with anticancer activity from the wood of Millettia leucantha. Archives of Pharmacal Research, 2011. 34(6): p. 881-886.
30. Matkowski, A., W. Jamiolkowska-Kozlowska, and I. Nawrot, Chinese medicinal herbs as source of antioxidant compounds--where tradition meets the future. Curr Med Chem, 2013. 20(8): p. 984-1004.
31. Lang, J.-Y., et al., BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell, 2011. 20(3): p. 341-356.
32. Kastan, M.B. and J. Bartek, Cell-cycle checkpoints and cancer. Nature, 2004. 432(7015): p. 316-23.
33. Giglia-Mari, G., A. Zotter, and W. Vermeulen, DNA damage response. Cold Spring Harb Perspect Biol. 3(1): p. a000745-a000745.
34. Ladstein, R.G., et al., Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer, 2010. 10(1): p. 140.
35. Hoos, A., et al., High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer, 2001. 92(4): p. 869-874.
(此全文20240808後開放外部瀏覽)
電子全文
全文檔開放日期:2024/08/08
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
* *